Improved Paclitaxel formulation hints at new chemotherapy approach.
Garber
Ken
K
D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000737:chemistry*; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D015195:Drug Design; D006801:Humans; D036103:Nanotechnology; D017239:Paclitaxel / Q000009:adverse effects / Q000737:chemistry*; D011092:Polyethylene Glycols / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D012995:Solubility; D043823:Taxoids / Q000009:adverse effects / Q000737:chemistry*
D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; C022131:cremophor; D011092:Polyethylene Glycols; D017239:Paclitaxel